HHT drug trial pulled before it even started

NCT ID NCT07255846

Terminated Disease control Sponsor: Terremoto Biosciences Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This was a planned early-stage study of a new drug called TER-1754 for people with hereditary hemorrhagic telangiectasia (HHT), a condition that causes frequent nosebleeds and abnormal blood vessels. The trial aimed to test safety and find the right dose, but it was withdrawn before any participants were enrolled. No results are available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TER-1754 (an AKT1 inhibitor)
What this could lead to: If this drug works, it could reduce nosebleeds and other bleeding symptoms in people with HHT, potentially improving daily life.
What could go wrong: This trial was withdrawn before enrolling any participants, so no data exists yet. As an early-phase study, safety and effectiveness are unknown, and many drug candidates fail at this stage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anemia arteriovenous hemangioma/malformation Epistaxis hereditary hemorrhagic telangiectasia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)

Contacts and locations

Show contact details

Locations

Innovative Hematology, Inc.

Indianapolis, Indiana, 46260, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.